Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer
Clinical trial NCT07589972 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07589972
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-20
- Primary completion
- 2027-12-31
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.